{ "meta": { "data_length": 1, "message": "Statement id stmt:hse:00702:b:2 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00702%3Ab%3A2", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002145, "timestamp_received": "2026-10-16T23:59:06.089804+00:00Z", "timestamp_returned": "2026-10-16T23:59:06.091949+00:00Z", "trace_id": "d4e6e9dc-3f03-42b8-9a36-f6f619b5d3f9" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hse:00702:b:2", "type": "Statement", "description": "The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.", "contributions": [ { "id": "ctrb:hse:2024-10-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2024-10-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } }, { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hse:00702", "type": "Document", "documentType": "Regulatory approval", "name": "Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Entrectinib Monotherapy - Adult, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6770/702_V2_Entrectinib_monotherapy.pdf", "urls": [ "https://healthservice.hse.ie/documents/6770/702_V2_Entrectinib_monotherapy.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-10-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:123", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C132146", "conceptType": "Disease", "name": "Any solid tumor", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146" ] } }, "objectTherapeutic": { "id": "tx:ncit:C114984", "conceptType": "Therapy", "name": "Entrectinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2197862", "code": "2197862", "name": "entrectinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2197862" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37496447", "code": "37496447", "name": "entrectinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37496447" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "ALK inhibition", "ROS1 inhibition", "NTRK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C114984", "code": "C114984", "name": "Entrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:65", "present": true, "subject": { "id": "bmkr:65", "type": "CategoricalVariant", "name": "v::NTRK3", "constraints": [ { "type": "AdjacencyConstraint", "orderKnown": false, "adjoinedElements": [ { "id": "gene:hgnc:8033", "conceptType": "Gene", "name": "NTRK3", "primaryCoding": { "id": "coding:hgnc:8033", "code": "HGNC:8033", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000140538", "code": "ENSG00000140538", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000140538" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:4916", "code": "4916", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/4916" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_001012338.3", "code": "NM_001012338.3", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3" ] } } ] }, { "type": "UnspecifiedElement" } ] } ], "extensions": [ { "name": "biomarker_type", "value": "Gene fusion" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hse:00702:b", "type": "Indication", "description": "For the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who: (i) have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.", "contributions": [ { "id": "ctrb:hse:2024-10-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2024-10-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } }, { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hse:00702", "type": "Document", "documentType": "Regulatory approval", "name": "Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Entrectinib Monotherapy - Adult, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6770/702_V2_Entrectinib_monotherapy.pdf", "urls": [ "https://healthservice.hse.ie/documents/6770/702_V2_Entrectinib_monotherapy.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-10-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." }, { "name": "reimbursement_scheme", "value": "CDS", "description": "Current scheme used to reimburse indication." }, { "name": "reimbursement_comment", "value": null, "description": "More details about the current reimbursement scheme(s)." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }